新入荷 再入荷

Cancer Immunotherapy Principles and Practice, Second Edition – Reflects Major Advances in Field of Immuno-Oncology and Cancer Immunology

flash sale icon タイムセール
終了まで
00
00
00
999円以上お買上げで送料無料(
999円以上お買上げで代引き手数料無料
通販と店舗では販売価格や税表示が異なる場合がございます。また店頭ではすでに品切れの場合もございます。予めご了承ください。
新品 5525円 (税込)
数量

商品詳細情報

管理番号 新品 :3046329054
中古 :3046329054-1
メーカー 936448602c98f 発売日 2025-04-24 12:51 定価 6500円
カテゴリ

Cancer Immunotherapy Principles and Practice, Second Edition – Reflects Major Advances in Field of Immuno-Oncology and Cancer Immunology

Cancer Immunotherapy Principles and Practice, Second Edition – Reflects  Major Advances in Field of Immuno-Oncology and Cancer ImmunologyCancer Immunotherapy Principles and Practice, Second Edition – Reflects Major Advances in Field of Immuno-Oncology and Cancer Immunology,Physicians' Cancer Chemotherapy Drug Manual 2023: 9781284272734: Medicine &  Health Science Books @ Amazon.comPhysicians' Cancer Chemotherapy Drug Manual 2023: 9781284272734: Medicine & Health Science Books @ Amazon.com,Cancer Immunotherapy Principles and Practice, Second Edition – Reflects  Major Advances in Field of Immuno-Oncology and Cancer Immunology:  9780826137425: Medicine & Health Science Books @ Amazon.comCancer Immunotherapy Principles and Practice, Second Edition – Reflects Major Advances in Field of Immuno-Oncology and Cancer Immunology: 9780826137425: Medicine & Health Science Books @ Amazon.com,The Neo-PLANET phase II trial of neoadjuvant camrelizumab plus concurrent  chemoradiotherapy in locally advanced adenocarcinoma of stomach or  gastroesophageal junction | Nature CommunicationsThe Neo-PLANET phase II trial of neoadjuvant camrelizumab plus concurrent chemoradiotherapy in locally advanced adenocarcinoma of stomach or gastroesophageal junction | Nature Communications,Frontiers | Phase II INTERACT-ION study: ezabenlimab (BI 754091) and mDCF  (docetaxel, cisplatin, and 5-fluorouracil) followed by chemoradiotherapy in  patients with Stage III squamous cell anal carcinomaFrontiers | Phase II INTERACT-ION study: ezabenlimab (BI 754091) and mDCF (docetaxel, cisplatin, and 5-fluorouracil) followed by chemoradiotherapy in patients with Stage III squamous cell anal carcinoma

 

商品情報の訂正

このページに記載された商品情報に記載漏れや誤りなどお気づきの点がある場合は、下記訂正依頼フォームよりお願い致します。

訂正依頼フォーム

商品レビュー

レビューの投稿にはサインインが必要です